A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus
Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in
Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma

Ziel dieser multizentrischen, randomisierten, doppelblinden, aktiv-komparator-kontrollierten, adaptiven Phase-2/3-Studie ist die Entwicklung einer neuartigen Kombinationsimmuntherapie, EIK1001 + Pembrolizumab, für die Behandlung des Melanoms

Eine multizentrische, randomisierte, offene Phase-2/3-Studie zur Untersuchung von Zanzalintinib versus Everolimus bei Patienten mit vorbehandelten, nicht resezierbaren, lokal fortgeschrittenen oder metastasierten neuroendokrinen Tumoren. 

Long-Term Follow up Protocol for subjects treated with gene-modified T Cells

A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH RESECTABLE STAGE III AND IV MELANOMA

An International Clinical Program for the diagnosis and Treatment of children, adolescents and young adults with ependymoma